fingolimod hydrochloride has been researched along with Heart Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| An, S; Gao, C; Huang, J; Jiang, R; Luo, H; Qian, Y; Song, Y; Zhang, J; Zhao, X | 1 |
| Haegele-Link, S; Humm, A; Hundsberger, T; Kaegi, G; Mueller, SK; Sauter, R; Tettenborn, BE; Vehoff, J | 1 |
| Barrero, F; En Representacion de Los Investigadores Del Estudio Ms Next, ERLIDEMN; Garcia, E; Mallada-Frechin, J; Martinez-Gines, ML; Marzo-Sola, ME; Meca-Lallana, V; Ricart, J | 1 |
| Bijarnia, M; Comi, G; Gold, R; Gottschalk, R; Kappos, L; Palace, J; Siever, A; Tomic, D; von Rosenstiel, P | 1 |
| Dillman, R; Franklin, MA; Happe, LE; Marshall, LZ | 1 |
| Gao, E; He, Y; Lee, Y; Tao, L; Wang, W; Xia, Y; Xin, C; Yan, W; Zhang, F; Zhang, H; Zhang, L; Zhao, S; Zhou, F; Zhu, D | 1 |
| Chun, J; Cohen, JA | 1 |
| Cocco, G | 1 |
| Cao, F; Fan, L; Gao, H; Tao, L; Wang, H; Wei, L; Yin, Z; Zhang, R | 1 |
1 review(s) available for fingolimod hydrochloride and Heart Diseases
| Article | Year |
|---|---|
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Topics: Animals; Central Nervous System; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Heart Diseases; Humans; Immunosuppressive Agents; Infections; Liver Diseases; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Respiration Disorders; Sphingosine | 2011 |
2 trial(s) available for fingolimod hydrochloride and Heart Diseases
| Article | Year |
|---|---|
Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
Topics: Adolescent; Adult; Blood Pressure; Female; Fingolimod Hydrochloride; Follow-Up Studies; Heart Diseases; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Time Factors; Valsalva Maneuver; Young Adult | 2017 |
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Topics: Adolescent; Adult; Age Factors; Aged; Bradycardia; Disability Evaluation; Electrocardiography; Endpoint Determination; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Diseases; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Safety; Propylene Glycols; Sphingosine; Treatment Outcome; Young Adult | 2014 |
6 other study(ies) available for fingolimod hydrochloride and Heart Diseases
| Article | Year |
|---|---|
Fingolimod Attenuates Lung Injury and Cardiac Dysfunction after Traumatic Brain Injury.
Topics: Acute Lung Injury; Animals; Brain Injuries, Traumatic; Cardiac Output; Cytokines; Disease Models, Animal; Echocardiography; Fingolimod Hydrochloride; Heart Diseases; Lung; Male; Mice; Mice, Inbred C57BL; Myocardium; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
[Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Topics: Adult; Disease Progression; Drug Resistance; Drug Substitution; Female; Fingolimod Hydrochloride; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies | 2018 |
Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis.
Topics: Female; Fingolimod Hydrochloride; Health Care Costs; Heart Diseases; Hospitalization; Humans; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Retrospective Studies; Sphingosine | 2014 |
Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction.
Topics: Animals; Animals, Newborn; Cytokines; Fingolimod Hydrochloride; Heart Diseases; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocarditis; Myocytes, Cardiac; Phosphotransferases (Alcohol Group Acceptor); Rats, Sprague-Dawley; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Transfection; Ultrasonography | 2016 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Factor V; Fingolimod Hydrochloride; Heart; Heart Diseases; Heart Failure; Humans; Hypertension; Immunosuppressive Agents; Male; Middle Aged; Mitral Valve Insufficiency; Multiple Sclerosis; Mutation; Myocardium; Propylene Glycols; Pyrazoles; Sjogren's Syndrome; Sphingosine; Sulfonamides | 2012 |
FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1/3 in diabetic heart disease.
Topics: Apoptosis; Base Sequence; Blotting, Western; Coronary Vessels; Diabetes Complications; DNA Primers; Fingolimod Hydrochloride; Heart Diseases; Humans; In Situ Nick-End Labeling; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microvessels; Neovascularization, Pathologic; Propylene Glycols; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine | 2012 |